NGS-based proteomics to uncover neurodegenerative molecular signatures

NGS-based proteomics to uncover neurodegenerative molecular signatures

Early access evaluation of Illumina Protein Prep by TATAA Biocenter on Cerebral Amyloid Angiopathy and Alzheimer's disease

Combining an innovative aptamer-based assay with NGS readout, Illumina Protein Prep (IPP) profiles more than 9,000 human proteins across more than 200 biological pathways, to maximise proteomics discovery power.​ Sofia Adolfsson, Scientific Officer at TATAA Biocenter, Sweden, shares IPP early data from Cerebral Amyloid Angiopathy (CAA) and Alzheimer’s Disease (AD) samples.

Join our live webinar and participate to the Q&A session to learn:

• The benefits of NGS-based proteomics and an overview of Illumina Protein Prep (IPP)
• How IPP assay enables the discovery of distinct molecular signatures for CAA and AD
• How IPP assay allows for highly sensitive and specific detection of both known and novel pathways involved in neurogenerative processes, opening new avenues for therapeutic discovery

Seize the chance to stay at the forefront of proteomics research.